|Bid||6.58 x N/A|
|Ask||6.69 x N/A|
|Day's Range||6.39 - 6.70|
|52 Week Range||4.48 - 8.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.27|
Subscribe to Yahoo Finance Plus to view Fair Value for NANOFH.HELearn more
The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, more line capacity added, ISMS certificate received, and a new near-term business target introduced: "Biologics pilot line for GMP in 2022".
The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross margin forcefully breaks through 90 per cent. Letter of intent signed for the development, manufacturing, and commercialization of a by nanoforming improved version of a current blockbuster drug.
Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development projects.